Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Mirati Therapeutics, Inc. MRTX
$48.26
+$0.14 (0.29%)
На 18:00, 12 мая 2023
+111.56%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
2769797952.00000000
-
week52high
101.30
-
week52low
32.96
-
Revenue
12436000
-
P/E TTM
-3
-
Beta
1.03287100
-
EPS
-13.86000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JMP Securities | Market Outperform | Market Outperform | 08 авг 2022 г. |
| Citigroup | Buy | Buy | 07 июл 2022 г. |
| Stifel | Buy | Buy | 07 июн 2022 г. |
| JMP Securities | Market Outperform | Market Perform | 07 июн 2022 г. |
| Goldman Sachs | Buy | Buy | 07 июн 2022 г. |
| Piper Sandler | Overweight | 15 сент 2022 г. | |
| JP Morgan | Overweight | Overweight | 26 сент 2022 г. |
| B. Riley Securities | Neutral | 28 окт 2022 г. | |
| SVB Leerink | Outperform | Outperform | 09 ноя 2022 г. |
| Citigroup | Buy | Buy | 16 ноя 2022 г. |
| Citigroup | Neutral | Buy | 09 дек 2022 г. |
| SVB Leerink | Outperform | Outperform | 08 дек 2022 г. |
| Piper Sandler | Overweight | Overweight | 08 дек 2022 г. |
| Oppenheimer | Perform | Perform | 08 дек 2022 г. |
| SVB Leerink | Outperform | Outperform | 14 дек 2022 г. |
| Needham | Hold | 14 дек 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 14 дек 2022 г. |
| Piper Sandler | Overweight | Overweight | 13 дек 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 27 янв 2023 г. |
| B. Riley Securities | Neutral | Neutral | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Davis Aaron I. | A | 7520 | 7520 | 20 янв 2023 г. |
| Davis Aaron I. | A | 47517 | 4444 | 20 янв 2023 г. |
| Hasnain Faheem | A | 10716 | 10716 | 20 янв 2023 г. |
| Hasnain Faheem | A | 15050 | 6333 | 20 янв 2023 г. |
| Cherrington Julie M | A | 7520 | 7520 | 20 янв 2023 г. |
| Cherrington Julie M | A | 4444 | 4444 | 20 янв 2023 г. |
| Johnson Craig A | A | 7520 | 7520 | 20 янв 2023 г. |
| Johnson Craig A | A | 10465 | 4444 | 20 янв 2023 г. |
| BAUM CHARLES M | A | 7520 | 7520 | 20 янв 2023 г. |
| BAUM CHARLES M | A | 173221 | 4444 | 20 янв 2023 г. |
Новостная лента
Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up
Zacks Investment Research
10 мая 2023 г. в 12:55
Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday.
Mirati Therapeutics, Inc. (MRTX) Q1 2023 Earnings Call Transcript
Seeking Alpha
09 мая 2023 г. в 22:44
Mirati Therapeutics, Inc. (NASDAQ:MRTX ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Ryan Asay – Vice President-Corporate Affairs David Meek – Chief Executive Officer Ben Hickey – Chief Commercial Officer Alan Sandler – Chief Medical Officer Jamie Christensen – Chief Scientific Officer Laurie Stelzer – Chief Financial Officer Conference Call Participants Michael Schmidt – Guggenheim Tyler Van Buren – TD Cowen Gena Wang – Barclays Jonathan Miller – Evercore ISI Mike Ulz – Morgan Stanley Ben Burnett – Stifel Maury Raycroft – Jefferies Silvan Tuerkcan – JMP Securities Eric Joseph – JPMorgan Yigal Nochomovitz – Citi Andy Fleszar – B. Riley Securities Jay Olson – Oppenheimer Ami Fadia – Needham Operator Good afternoon, and welcome to the Mirati Therapeutics First Quarter 2023 Earnings Call.
Mirati (MRTX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 19:07
Mirati (MRTX) came out with a quarterly loss of $3.18 per share versus the Zacks Consensus Estimate of a loss of $3.47. This compares to loss of $3.40 per share a year ago.
Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023
PRNewsWire
25 апр 2023 г. в 16:30
SAN DIEGO , April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023. During a conference call at 4:30 p.m.
Mirati's Krazati: A Strong Competitor In The KRAS G12C-Mutated NSCLC Market
Seeking Alpha
20 мар 2023 г. в 03:43
Mirati Therapeutics specializes in developing cancer treatments targeting genetic and immunological causes, with Krazati being their first FDA-approved product. Krazati is used to treat adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).